About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Tumor-infiltrating Lymphocytes (S-TILs) Irrelevant to Trastuzumab Usage in HER-2+ Breast Cancer

by Kalyani Thivakaran on December 11, 2014 at 12:58 PM
Font : A-A+

 Tumor-infiltrating Lymphocytes (S-TILs) Irrelevant to Trastuzumab Usage in HER-2+ Breast Cancer

Immune function marker used for better prediction of outcomes in patients undergoing chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker, the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy, appears irrelevant when trastuzumab is used.

And since trastuzumab, and not chemotherapy alone, is the standard of care for the HER2-positive sub-class of breast cancer, there is no need to test for these lymphocytes in HER2-positive patients in order to predict outcome, say researchers from Mayo Clinic in Florida.

Advertisement

These findings, presented at the 2014 San Antonio Breast Cancer Symposium, don't mean that immune function in this class of cancer isn't important, just that it is likely more complicated than measuring the number of these lymphocytes, says the study's lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida.

"Researchers are really interested in the different components of the immune system as a predictor of the natural history of breast cancer and benefit from different therapies, but it may be that when trastuzumab is used, it is the function of the immune system and not the number of lymphocytes that is important," Dr. Perez says.
Advertisement

She also pointed out that S-TILs can do two things; they can promote the killing of tumors but they can also actually create substances to help cancer grow. "We don't know what effect they have when trastuzumab is used," she says.

The study measured S-TILs at diagnosis in about 1,000 patients with early stage HER2-positive breast cancer enrolled in the N9831 study, which tested chemotherapy alone or chemotherapy with trastuzumab. Only patients treated with chemotherapy alone showed improved recurrence-free survival when the S-TILs score was high.

The findings contradict a smaller study of HER2-positive patients that found increased levels of S-TILs were linked to increased trastuzumab benefit. That study suggested that tumors of patients with HER2-positive disease should be tested for their S-TILs score in order to determine therapy benefit.

"Ours is a much more definitive study, showing this testing is not necessary in this subset of patients with HER2-positive breast cancer," Dr. Perez says.

"This study is part of a series we are conducting to determine which patients should use trastuzumab. We are now giving it to everyone whose tumors are HER2-positive, but not every patient benefits," she says.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Ten Fruits for Diabetics
Natural Supplements Help Reverse Hair Loss during Menopause
Ways to Manage Stress during COVID-19 Pandemic
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Women and Cancer Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Chronic Lymphocytic Leukemia Breast Cancer Facts Cancer Facts Cancer Tattoos A Body Art 

Recommended Reading
US Treatment Market for HER2-Positive Breast Cancer to More Than Treble in Value by 2023
A new report from GlobalData says that the US treatment market for HER2-positive breast cancer will ...
Male Breast Cancer
Most cases of male breast cancer are diagnosed between the ages of 60 and 70 years. Treatment of ......
Breast Cancer Treatment May Cause Heart Damage
Therapies used in breast cancer may cause heart damage. Be informed; know your options. Save the ......
Exercise Improves Survival After Breast Cancer Diagnosis
Breast cancer patients can improve survival post diagnosis by engaging in moderate but regular ......
Breast Biopsy
Breast biopsy involves removing a sample of breast tissue to determine whether it is cancerous or .....
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is one of the most common types of adult leukemia and is consider...
Mastitis
Mastitis is a common cause of tenderness, swelling and pain in breast, owing to inflammation in the ...
Pagets disease of the breast
A detailed description of the Paget's disease of the breast, characteristic signs and symptoms, dete...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of l...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use